Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Up 16.5% in October

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 29,600 shares, a growth of 16.5% from the September 30th total of 25,400 shares. Approximately 2.3% of the company’s shares are short sold. Based on an average daily trading volume, of 16,200 shares, the short-interest ratio is presently 1.8 days.

Creative Medical Technology Trading Up 10.4 %

Shares of CELZ opened at $4.23 on Thursday. Creative Medical Technology has a twelve month low of $2.65 and a twelve month high of $10.28. The firm has a market capitalization of $5.70 million, a P/E ratio of -1.23 and a beta of 2.09. The stock’s fifty day simple moving average is $3.51 and its 200 day simple moving average is $3.82.

Creative Medical Technology (NASDAQ:CELZ) last released its quarterly earnings data on Friday, August 9th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.27). The firm had revenue of $0.01 million during the quarter. Sell-side analysts predict that Creative Medical Technology will post -3.29 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Creative Medical Technology stock. Virtu Financial LLC bought a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 16,374 shares of the company’s stock, valued at approximately $85,000. Virtu Financial LLC owned 1.21% of Creative Medical Technology at the end of the most recent quarter. 1.42% of the stock is owned by hedge funds and other institutional investors.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.